How Does Latanoprost Work to Make Eyelashes and Possibly Scalp Hair Grow?

When we talk about latanoprost, we are talking about a drug that was never intended to make eyelashes grow. The FDA approved it in 1996 strictly as an eye drop for glaucoma, a condition that increases pressure inside the eye and can damage the optic nerve. The drug's stated job is to mimic prostaglandins, natural molecules in the body that regulate inflammation, circulation, and, as it later turned out, even hair follicle behavior. The curiosity began when patients treated for glaucoma started to notice that their eyelashes looked longer, darker, and denser. What began as an unintended effect in ophthalmology quietly entered the field of cosmetic science.

The Biological Mechanism Behind the Growth

To understand why eyelashes change under latanoprost, we need to talk about the hair growth cycle. Hair does not grow continuously. It passes through phases: anagen (growth), catagen (transition), and telogen (resting). The balance of these phases determines whether hair actively lengthens or simply sheds and falls out. Prostaglandins are described as influencing this cycle by pushing follicles into the anagen phase and keeping them there longer than usual. Latanoprost, as a prostaglandin analog, appears to extend this growth phase. This is the mechanism usually given for why eyelashes exposed to the drug become longer and thicker. The same principle could, at least in theory, apply to scalp hair, but the evidence there is much weaker.

Eyelash changes under prostaglandin analogues have been described in the ophthalmology literature, not only in anecdotes. In 2002, Johnstone and Albert reviewed prostaglandin-induced hair growth in Survey of Ophthalmology. Their account was built on patient observations rather than controlled experiments, but it described a consistent link between prostaglandin analogs and eyelash changes. We could not verify a published controlled trial that measured eyelash length in latanoprost-treated glaucoma patients, so this part of the evidence should be read as observational. It is also worth noting that the prostaglandin analog approved for eyelash growth is bimatoprost (Latisse), approved in 2008 — using latanoprost for eyelashes is itself off-label.

What Happens When We Test It on Scalp Hair?

The scalp is different from the eyelid. While eyelashes grow in short cycles of a few months, scalp hairs can remain in the anagen phase for years.

This makes the biology more complex. A pilot study conducted by Blume-Peytavi and colleagues in 2012 investigated the topical application of latanoprost 0.1% on the scalp of 16 men with androgenetic alopecia. For 24 weeks, the drug was applied to small patches of the scalp, and results were evaluated with photographic hair counts. The authors reported an increase in hair density compared with placebo. Yet the limitations were impossible to ignore: the study was small, ran less than six months, and covered only localized scalp areas. Findings of this size are not evidence of a reliable treatment. Note also that the 0.1% strength used in that research formulation is twenty times the 0.005% concentration of the licensed eye drop.

Animal work points in the same direction without settling it. Uno and colleagues in 2002 tested topical latanoprost on the bald scalp of the stump-tailed macaque. In this pilot of 8 monkeys, the eye-drop strength (50 µg/mL) for 5 months caused minimal hair growth; only a tenfold higher strength, given to 2 monkeys for a further 3 months, produced moderate to marked regrowth. While this supports biological plausibility, monkeys and humans do not share identical hair growth cycles. Translation to human scalp remains speculative.

Why Isn't It Used Widely for Baldness?

If latanoprost can make eyelashes grow, why isn't it already a treatment for hair loss? The answer lies in evidence and practicality. For eyelashes, there are consistent clinical reports and visible results within months. For scalp hair, the published evidence is limited to one small pilot study and animal models. The FDA has not approved latanoprost for hair loss, which means any use outside the eye is off-label. Applying eye drops to a small eyelid margin is practical. Spreading a similar solution across an entire scalp daily is not. On top of that, minoxidil and finasteride already dominate the field of hair loss, with large-scale trials behind them. Latanoprost has not reached that level of validation.

The picture the literature supports is this: the eyelash effect is the best documented one, because eyelashes are short-cycle hairs with quick turnover. On the scalp, the reported effects are weak, based on very few participants, and under-researched. Technical terms like "prostaglandin analog" or "hair growth cycle" describe real mechanisms, but translating them into a dependable treatment is not yet justified. The science is still narrow in scope, with limited populations, short timelines, and methodological gaps. Until larger and longer studies are published, latanoprost for scalp hair growth remains an interesting but unproven possibility.

Latanoprost is a prescription medicine, and putting an eye drop on the scalp is an off-label use with no established dose, no safety data at that surface area, and no approval behind it. Talk to a doctor or pharmacist before starting, stopping or combining latanoprost.

References

Blume-Peytavi, U., Lönnfors, S., Hillmann, K., & Garcia Bartels, N. (2012). A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. Journal of the American Academy of Dermatology, 66(5), 794–800. Retrieved from https://pubmed.ncbi.nlm.nih.gov/21875758/

Johnstone, M. A., & Albert, D. M. (2002). Prostaglandin-induced hair growth. Survey of Ophthalmology, 47(Suppl 1), S185–S202. Retrieved from https://pubmed.ncbi.nlm.nih.gov/12204716/

Uno, H., Zimbric, M. L., Albert, D. M., & Stjernschantz, J. (2002). Effect of latanoprost on hair growth in the bald scalp of the stump-tailed macaque: a pilot study. Acta Dermato-Venereologica, 82(1), 7–12. Retrieved from https://pubmed.ncbi.nlm.nih.gov/12013211/